Cargando…

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany

BACKGROUND: In this study we calculate the effectiveness of pneumococcal conjugate vaccines (PCV) against invasive pneumococcal disease (IPD) among children under the age of two years using the indirect cohort method. We also discuss the timeliness of vaccination and the residual cases of vaccine ty...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Linden, Mark, Falkenhorst, Gerhard, Perniciaro, Stephanie, Fitzner, Christina, Imöhl, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985133/ https://www.ncbi.nlm.nih.gov/pubmed/27526117 http://dx.doi.org/10.1371/journal.pone.0161257

Ejemplares similares

Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany
por: van der Linden, Mark, et al.
Publicado: (2015)

Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era
por: van der Linden, Mark, et al.
Publicado: (2015)

Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany
por: Perniciaro, Stephanie, et al.
Publicado: (2019)

Invasive Pneumococcal Disease in Refugee Children, Germany
por: Perniciaro, Stephanie, et al.
Publicado: (2018)

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden
por: Galanis, Ilias, et al.
Publicado: (2016)

Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
por: Tomczyk, Sara, et al.
Publicado: (2018)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

1480. Incidence of Non-Invasive Pneumococcal Pneumonia in Children in the United States before and after Introduction Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018
por: Hu, Tianyan, et al.
Publicado: (2020)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The Gambia
por: Roca, Anna, et al.
Publicado: (2015)

2703. Pneumococcal Carriage of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Non-PCV13 Serotypes among Greek Children Vaccinated with PCV13 in a 3 + 1 Schedule During the First 6 years after the Fourth Dose of PCV13
por: Syrogiannopoulos, George A, et al.
Publicado: (2019)

1180. Comparing Changes in Pneumococcal Meningitis Incidence to all Invasive Pneumococcal Disease Following Introduction of PCV10 and PCV13: The PSERENADE Project
por: Yang, Yangyupei, et al.
Publicado: (2021)

1735. Impact of Children Universal Pneumococcal Vaccination (PCV7v/PCV13v) on Pneumococcal Invasive Disease Hospitalizations in a Private General Hospital, Uruguay
por: Sanchez-Varela, Mercecedes, et al.
Publicado: (2023)

Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany
por: Imöhl, Matthias, et al.
Publicado: (2015)

Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 2015
por: Regev-Yochay, Gili, et al.
Publicado: (2018)

Population genomics of pneumococcal carriage in South Africa following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) immunization
por: Javaid, Nida, et al.
Publicado: (2022)

Invasive pneumococcal surveillance to assess the potential benefits of extended spectrum conjugate vaccines (PCV15/PCV20) in older adults
por: Humphreys, Hilary, et al.
Publicado: (2023)

Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.
por: Pilishvili, Tamara, et al.
Publicado: (2017)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

Stability of the pneumococcal population structure in Massachusetts as PCV13 was introduced
por: Chang, Qiuzhi, et al.
Publicado: (2015)

Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR)
por: Abu Seir, Rania, et al.
Publicado: (2018)

Epidemiology and distribution of 10 superantigens among invasive Streptococcus pyogenes disease in Germany from 2009 to 2014
por: Imöhl, Matthias, et al.
Publicado: (2017)

The Impact of Pneumococcal Conjugate Vaccine (PCV) Coverage Heterogeneities on the Changing Epidemiology of Invasive Pneumococcal Disease in Switzerland, 2005–2019
por: Oyewole, Oluwaseun Rume-Abiola, et al.
Publicado: (2021)

Limited indirect effects of an infant pneumococcal vaccination program in an aging population
por: van der Linden, Mark, et al.
Publicado: (2019)

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
por: Dirmesropian, S, et al.
Publicado: (2015)

1441. Doses of 13-Valent Conjugated Pneumococcal Vaccine (PCV13) for Patients With Multiple Myeloma (MM)
por: Sun, Hsin-Yun, et al.
Publicado: (2018)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
por: Izurieta, Patricia, et al.
Publicado: (2021)

Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study
por: Perniciaro, Stephanie, et al.
Publicado: (2021)

1479. Incidence of Acute Otitis Media in Children in the United States before and after the introduction of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018
por: Hu, Tianyan, et al.
Publicado: (2020)

Invasiveness potential of pneumococcal serotypes in children after introduction of PCV13 in Blantyre, Malawi
por: Kirolos, Amir, et al.
Publicado: (2023)

Correction: Limited indirect effects of an infant pneumococcal vaccination program in an aging population
por: van der Linden, Mark, et al.
Publicado: (2020)

1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
por: Pilishvili, Tamara, et al.
Publicado: (2020)

Correction to “Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study”
por: Perniciaro, Stephanie, et al.
Publicado: (2022)

Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
por: Suwantika, Auliya A., et al.
Publicado: (2020)

1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Buchwald, Ulrike, et al.
Publicado: (2018)

The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
por: Feldman, Charles, et al.
Publicado: (2020)

Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
por: Bennett, Julia C., et al.
Publicado: (2021)

1173. Changes in Invasive Pneumococcal Disease Incidence Following Introduction of PCV10 and PCV13 Among Children < 5 Years: The PSERENADE Project
por: Bennett, Julia C, et al.
Publicado: (2021)

Estimating the Clinical and Economic Impact of Maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico
por: Wasserman, Matt, et al.
Publicado: (2017)

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
por: Atwood, Mark, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fp6frpbop7kqso49rb3lk212fj